OverviewSuggest Edit

Novartis researches, develops, manufactures, and markets a range of healthcare products. The Innovative Medicines segment offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as contact lenses and contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.

... Show more
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2017)126,000(+5%)
Job Openings2,777
Revenue (FY, 2017)$49.1 B(+2%)

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer of Novartis
Steven Baert

Steven Baert

Chief People & Organization Officer of Novartis
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer of Novartis
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research (NIBR)
Richard Francis

Richard Francis

CEO, Sandoz
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Show more

Novartis Office Locations

Novartis has offices in Basel, Surrey, Bangkok, Barcelona and in 33 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Núñez, AR
1851 Ramallo
Elsene, BE
108 Troonstraat
São Paulo, BR
90 Av. Professor Vicente Rao
Dorval, CA
385 Boulevard Bouchard
Chaoyang Qu, CN
1 Jianguomen Outer St
Show all (37)
Report incorrect company information

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $49.11 b in FY, 2017 which is a 1.2% increase from the previous period.
USD

Revenue (FY, 2017)

49.1b

Revenue growth (FY, 2016 - FY, 2017), %

1.2%

Gross profit (FY, 2017)

31.9b

Gross profit margin (FY, 2017), %

65%

Net income (FY, 2017)

7.7b

Cash (31-Dec-2017)

8.9b
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

53.6b49.4b48.5b49.1b

Revenue growth, %

(8%)(2%)1%

Cost of goods sold

17.3b17.4b17.5b17.2b

Gross profit

36.3b32.0b31.0b31.9b
USDFY, 2016FY, 2017

Cash

7.0b8.9b

Accounts Receivable

8.2b8.6b

Inventories

6.3b6.9b

Current Assets

24.9b28.2b
USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b6.7b7.7b

Cash From Operating Activities

11.9b11.5b12.6b

Purchases of PP&E

(2.4b)(1.9b)(1.7b)

Cash From Investing Activities

(10.8b)(3.4b)(3.1b)
USDY, 2017

Revenue/Employee

405.5k

Financial Leverage

1.8 x
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Advanced Accelerator ApplicationsOctober 30, 2017$3.90 b
AveXis$8.70 b

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 12.3% from Alcon, 20.5% from Sandoz and 67.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 6.5% from Japan , 5.1% from France, 7.5% from Germany, 34.5% from United States and 46.5% from Other

Report incorrect company information

Novartis Online and Social Media Presence

Embed Graph
Report incorrect company information

Novartis News and Updates

Global Eye Infections Treatment Market Size & Positive Long-Term Growth Outlook 2019-2025 : Allergan Inc., Alcon Laboratories Inc., Johnson & Johnson Ltd., Pfizer Inc., Merck & Co., Inc., Novartis

The market for eye disease treatments is on the rise due to population aging, increased prevalence of eye disease, increased corporate investment to launch new products, a health-conscious population, and free eye examination camps funded by local governments. Posted via Industry Today. Follow us o…

Cell and Gene Therapy Market – Major Technology Giants in Buzz Again | Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis

The “Global Cell and Gene Therapy Market” provides up-to-date information on current and future industry trends, enabling readers to identify products and services to increase revenue growth and profitability. Posted via Industry Today. Follow us on Twitter @IndustryToday

Biosimilar Drugs Market Growth & Key Business Strategies by Leading Industry Players Novartis, Celltrion, Biocon, Hospira, Merck Serono, Biogen idec, Genentech

Biosimilar Drugs market report gives a detailed overview of the dynamics of the industries, which impacts on the growth of businesses. The study comprises a blend of various segments such as drivers, restraints, and opportunities. The effective strategies are implemented by the various top-level key…

Trending Report on Systemic Hypertension Market 2019: By Top Leading Players like Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Sanofi, and Pfizer

Systemic Hypertension is high blood pressure in the systemic arteries - the vessels that carry blood from the heart to the body's tissues. High systemic blood pressure is usually caused by the constriction of the small arteries. Posted via Industry Today. Follow us on Twitter @IndustryToday

Congenital Adrenal Hyperplasia Market 2019 Global Analysis By Key Players – Fusion IP plc, Novartis AG, Mitsubishi Chemical Holdings, Johnson & Johnson, GlaxoSmithKline

WiseGuyReports.Com Publish a New Market Research Report On –“ Congenital Adrenal Hyperplasia Market 2019 Global Analysis By Key Players – Fusion IP plc, Novartis AG, Mitsubishi Chemical Holdings, Johnson & Johnson, GlaxoSmithKline”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Novartis CEO lauds Trump administration plan to overhaul rebates

Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits.
Show more
Report incorrect company information

Novartis Company Life and Culture

Report incorrect company information

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Steven Baert and Bertrand Bodson.

  • How many employees does Novartis have?

    Novartis has 126,000 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $49.1 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $389.8 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Urovant Sciences, Teva Pharmaceuticals and Merck.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Forum 1, Novartis Campus, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Surrey, Bangkok, Barcelona and in 33 other locations.

  • How many offices does Novartis have?

    Novartis has 37 offices.